Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Urch Publishing Reports | World Market for Addiction Disorders, 2009-2016

World Market for Addiction Disorders, 2009-2016

Examines the market for addiction pharmacotherapies currently estimated at US$2 billion

The substance dependence field is transforming into a high-growth market opportunity. Supported by the success of Pfizer's recently launched Chantix/Champix, which is on track for blockbuster status in the smoking cessation sector, pharmacotherapies in development for alcohol, narcotic, and nicotine dependencies are poised to radically change the addiction treatment landscape in this difficult-to-treat patient population.

The report estimates that the current market for addiction disorders is valued at US$3.2 billion and this is forecast to increase 19% to US$3.8 billion by 2016.

The World Market for Addiction Disorders, 2009 2016: Future Therapies for Substance Dependence and Impulse Control, will introduce the reader a specialty pharmaceutical market which is positioned for high-growth based on analysis of marketed and pipeline drugs, company activities, and addiction disorder demographics.

Therapy area forecasting and illustrative comparative sales data is presented to gain insight into leading products with sales estimates to 2016.

Objectives of Report
The objectives of this 80 page report are to provide an in-depth analysis of the global addiction pharmacotherapeutic market. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. The reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.

Report Highlights Include:

The current market for addiction disorders is valued at US$3.2 billion, up from US$2 billion in 2005
Critical analysis of alcohol, cocaine, opiate, and nicotine addictions
Review of epidemiological, aetiological, and demographic data for addiction disorders
Analysis of over 10 key marketed products and inclusion of 34 R&D candidates identified in preclinical to clinical stages of development for addiction disorders
Sales estimates (US$) to 2012 for major therapy areas
Strategic insights for life-cycle optimization and product development
Critical evaluation of leading addiction pharmacotherapies
Emerging markets identified and sector analysis
Trend analysis of industry events and activities over past 2 years
Detailed R&D themes and clusters by addiction area
Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
High revenue-yielding prospects identified with projected sales estimations
R&D pipeline positioning for novel candidates
Market insights for product development and drug promotion

What you can learn from this report:

Which addiction therapies are the current and potential future market leaders
How companies are reformulating products for addiction indications
Which premarket addiction pharmacotherapies are identified as high-value products
Which companies are developing drugs for addiction disorders
Sales predictions to 2016 for addiction pharmacotherapies
What the likely impact of pipeline products will be on value growth of the addiction market over the 10 years
Which addiction subsectors could be niche market opportunities
What the future outlook holds for addiction pharmacotherapies
Insight into R&D trends for alcohol, cocaine, opiate, and nicotine addictions
Which molecules and compounds are main R&D clusters for dependency disorders
Which of the pipeline candidates are top prospects in the addiction market over the next decade and to 2025

Report Contains:

Detailed survey and analysis of the current and future global addiction disorder market
Comprehensive update on key marketed products indicated for alcohol, narcotic, and nicotine dependency disorders
Review of epidemiological, demographic, aetiological, and therapeutic data associated with addiction disorders
Market analysis and insight of key addiction pharmacotherapies and pipelines
Market value predictions of individual marketed products to 2016
Insight and trend analysis of pipeline products for addiction disorders
Review of promising pipeline products and potential market opportunities
Extensive coverage of the R&D pipeline for addiction disorders
Guide to leads for potential licensing opportunities

Companies Mentioned in this Report include
Acrux
Alkermes
Biotie Therapies
Brookwood Pharmaceuticals
Catalyst Pharma Partners
Celtic Pharmaceuticals
Cephalon
Drug Abuse Sciences
Elbion
Eli Lilly
Forest Laboratories
GlaxoSmithKline
Impax Laboratories
InterveXion Therapeutics
J&J
Janssen-Cilag
Krele Pharma
Merck Serono
Nabi Biopharmaceuticals
Pfizer
Sanofi-Aventis
Somaxon Pharma.
STADA
Synosia Therapeutics
Targacept
Teva Pharmaceuticals
Titan Pharmaceuticals
WorldMeds
Yaupon Therapeutics

Publication Date October 2009
Pages 81
Tables 17
Figures 7

Table of Contents

Price

Single Use Licence PDF $2340.00

Print $2390.00

Company-wide Licence PDF $13590.00

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions